Review
With the prevalence of type 2 diabetes increasing, this article discusses how it is essential that healthcare professionals assess how their patients’ current diabetes treatment is being managed to avoid further weight gain in those who are already overweight or obese.
Review
Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options.
Unlike previously available agents, sodium-glucose co-transporter 2 inhibitors offer an insulin-independent mechanism for improving blood glucose levels, since they promote urinary glucose excretion by inhibiting glucose reabsorption in the kidney.
In this article, the author discusses empagliflozin and based on available data, it appears that this drug may be a useful option in a range of patients; however, clinical decisions will be better informed by the results of ongoing studies, in particular, a large cardiovascular outcome study (EMPA-REG OUTCOME™).
Case Report
It is estimated that by 2050, the majority of Britain’s population will be obese. In this article, Dr Henry Purcell discusses the cardiovascular consequences of obesity and what needs to be done to equip healthcare professionals with the tools and training to help prevent and treat weight-related diseases.